Riskpilot← Back to searchSign inGet full accessUnibio KSA ApS
APSActiveCVR 40762272Langebjerg 1Research and experimental development on natural sciences and engineering · NACE 7210Est. 2019— employees
Revenue 2024
—
EBITDA margin
—
-511% vs 2023
Equity ratio
-15.3%
Financial strength
Net profit 2024
DKK -107K
-494% vs 2023
| Revenue | — | — |
| EBITDA | DKK -110K | -511% |
| Net profit | DKK -107K | -494% |
| Total assets | DKK 451K | -18% |
| Equity | DKK -69K | -282% |
| Employees | — | — |
Legal name
Unibio KSA ApS
CVR number
40762272
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
28. august 2019
Share capital
DKK 50.000
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den administrerende direktør i forening med en anden direktør
Company purpose
Selskabets formål er forskning, udvikling, produktion, fabrikation, handel og andet i forbindelse hermed beslægtet virksomhed efter selskabets skøn
Address
Langebjerg 1
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | -12 | -14 | -18 | — | — |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -12 | -14 | -18 | -18 | -110 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -12 | -14 | -18 | -18 | -110 |
| Net financials | 0 | 0 | 0 | 0 | 3 |
| Profit before tax | -12 | -14 | -18 | -18 | -107 |
| Tax | -0 | -3 | 3 | -0 | -0 |
| Net profit | -12 | -11 | -21 | -18 | -107 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 50 | 40 | 68 | 552 | 451 |
| Equity | 38 | 27 | 56 | 38 | -69 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 12 | 13 | 12 | 514 | 520 |
| Total debt | 12 | 13 | 12 | 514 | 520 |
EBITDA margin
-11000000.0%
This company
15.8%
Market median
-69620353% vs market
20202024
Equity ratio
-15.3%
This company
38.2%
Market median
-140% vs market
20202024
Return on equity
-10700000.0%
This company
18.4%
Market median
-58152274% vs market
20202024
Net profit margin
-10700000.0%
This company
8.1%
Market median
-132098865% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
7.54×
This company
0.62×
Market median
-1116% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2019-08-28 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
DR Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
HB Chief Executive Officer | Chief Executive Officer | 2019 | — | — |
JB Management | Management | 2019 | — | — |
JD Management | Management | 2024 | — | — |
SO Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
UNIBIO A/S | Company | 100.0% | 100.0% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
UNIBIO A/S
Unibio KSA ApS Board members of Unibio KSA ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| David Richard Henstrom | Chief Executive Officer | 0 companies |
| Henrik Busch-Larsen | Chief Executive Officer | 0 companies |
| Jakob Brix Christensen | Management | 0 companies |
| Jess Dragheim | Management | 0 companies |
| Søren Olrik Eklund | Chief Executive Officer | 0 companies |